Healthy adults
Conditions
Interventions
Ingestion of the grifola frondosa extract tablets daily for 8 weeks.
Ingestion of the placebo tablets daily for 8 weeks.
Sponsors
Hokkaido Information University
Forest Products Research Institute, Forest Research Department, Local Independent Administrative Agency Hokkaido Research Organization
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects whose arteriosclerotic index is more than 2.0. 2. Subjects who agree to participate in the current study with a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects who are under treatment and medication for hyperlipidemia and diabetes. 2. Subjects with serious cerebrovascular, cardiac, hepatic, renal and / or endocrine and metabolic disorders, or affected with an infectious disease which is required to report to the authorities. 3. Subjects with familial hypercholesterolemia. 4. Subjects who have a history of gastrectomy, gastrorrhaphy, enterectomy and/ or other serious gastrointestinal surgeries. 5. Subjects with unusually high and/or low blood pressure, or with abnormal hematological data. 6. Subjects who have a serious anemia. 7. Pre- or post-menopausal women having obvious changes in physical condition. 8. Subjects who have a history of allergy or sensitivity to medicine and / or food (especially mushrooms). 9. Subjects who regularly take drugs, functional foods and/or supplements (EPA, DHA, MCT, phytosterol, sesamin, turmeric, polyphenols, dietary fiber, etc.) which would affect the blood lipid levels. 10. Subjects who regularly take drugs, functional foods and/or supplements (containing dietary fiber such as indigestible dextrin, polyphenol etc.) which would affect blood glucose. 11. Heavy smokers, alcohol addicts or subjects with irregular lifestyle. 12. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood fractions within 2 weeks prior to this study. 13. Pregnant or lactating women or women expect to be pregnant during the clinical trial. 14. Subjects who participated in other clinical trials within the last one month prior to the clinical trial. 15. Any other medical reasons judged by the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Arteriosclerotic index | — |
Secondary
| Measure | Time frame |
|---|---|
| TC, LDL-C, HDL-C, TG, non HDL-C, ox-LDL, TBARS, hs-CRP, adiponectin, fasting blood glucose, HbA1c, body weight, BMI, body fat rate | — |
Countries
Japan
Contacts
Public ContactDir. Prof. Jun NISHIHIRA, M.D., Ph.D.
Hokkaido Information University Health Information Science Center
Outcome results
None listed